» Articles » PMID: 12884865

Suppressor Activity of Anergic T Cells Induced by IL-10-treated Human Dendritic Cells: Association with IL-2- and CTLA-4-dependent G1 Arrest of the Cell Cycle Regulated by P27Kip1

Overview
Journal Eur J Immunol
Date 2003 Jul 30
PMID 12884865
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously shown that human IL-10-treated dendritic cells (DC) induce an antigen-specific anergy in CD4+ T lymphocytes. These anergic T cells are characterized by an inhibited proliferation, a reduced production of IL-2, and additionally display antigen-specific suppressor activity. In this study we investigated the mechanisms underlying the anergic state and regulatory function of these T cells. We did not observe enhanced rates of programmed cell death of anergic CD4+ suppressor T cells compared to T cells stimulated with mature DC. Cell cycle analysis by DNA staining and Western blot experiments revealed an arrest of anergic CD4+ T suppressor cells in the G1 phase. High levels of the IL-2-dependent cyclin-dependent kinase (cdk) inhibitor p27Kip1 were found in anergic CD4+ suppressor T cells resulting in an inhibited activation of retinoblastoma protein and an arrest of cell cycle progression in the G1 phase. Addition of IL-2, but not blocking of the CTLA-4 pathway restored the proliferation of the suppressor T cells. In contrast, both treatments induced a down-regulation of p27Kip1 and acomplete inhibition of the antigen-specific regulatory function as demonstrated by high proliferation and enhanced IFN-gamma production of co-cultured T cells. Further experiments demonstrated that p27Kip-expressing regulatory CD4+CD25+ T cells did not contribute to induction of T cell anergy in this model. Our data show that regulatory function of anergic CD4+ suppressor T cells is associated with an arrest in the G1 phase of the cell cycle mediated by increased levels of the IL-2- and CTLA-4-dependent cdk inhibitor p27Kip1.

Citing Articles

An overview on the interaction between non-coding RNAs and CTLA-4 gene in human diseases.

Ebrahimi A, Barati T, Mirzaei Z, Fattahi F, Mansoori Derakhshan S, Shekari Khaniani M Med Oncol. 2024; 42(1):13.

PMID: 39585522 DOI: 10.1007/s12032-024-02552-w.


Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.

Ebrahimi N, Abdulwahid A, Mansouri A, Karimi N, Bostani R, Beiranvand S Cell Mol Life Sci. 2024; 81(1):106.

PMID: 38418707 PMC: 10902086. DOI: 10.1007/s00018-023-05098-8.


Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.

Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X Front Pharmacol. 2022; 13:955701.

PMID: 36133806 PMC: 9483178. DOI: 10.3389/fphar.2022.955701.


The Dendritic Cell Dilemma in the Skin: Between Tolerance and Immunity.

Scheib N, Tiemann J, Becker C, Probst H, Raker V, Steinbrink K Front Immunol. 2022; 13:929000.

PMID: 35837386 PMC: 9275407. DOI: 10.3389/fimmu.2022.929000.


Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?.

Hossain S, Lynch-Sutherland C, Chatterjee A, Macaulay E, Eccles M Epigenomes. 2021; 5(3).

PMID: 34968365 PMC: 8594685. DOI: 10.3390/epigenomes5030016.